Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | RXFP1 | Q9HBX9 | 4/20 | 0.54 |
| ▸ | PRNP | P04156 | 4/20 | 0.54 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.54 |
| ▸ | NPSR1 | Q6W5P4 | 3/20 | 0.51 |
| ▸ | MAPK10 | P53779 | 2/20 | 0.51 |
| ▸ | RAB9A | P51151 | 1/20 | 0.50 |
| ▸ | KMT2A | Q03164 | 5/20 | 0.49 |
| ▸ | MEN1 | O00255 | 4/20 | 0.49 |
| ▸ | L3MBTL1 | Q9Y468 | 5/20 | 0.46 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.46 |
| ▸ | LMNA | P02545 | 2/20 | 0.43 |
| ▸ | PTBP1 | P26599 | 1/20 | 0.43 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.42 |
| ▸ | KCNK2 | O95069 | 1/20 | 0.40 |
| ▸ | HPGD | P15428 | 2/20 | 0.40 |
| ▸ | MAPT | P10636 | 1/20 | 0.39 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2098479 | 0.76 | RXFP1 (0.53) | RXFP1PRNPKDM4ENPSR1MAPK10 | |
| SCHEMBL11029724 | 0.76 | PRNP (0.59) | RXFP1PRNPKDM4ENPSR1MAPK10 | |
| SCHEMBL8347789 | 0.76 | PRNP (0.59) | RXFP1PRNPKDM4ENPSR1MAPK10 | |
| Hydrochloric Acid SCHEMBL10708870 | 0.74 | PRNP (0.57) | RXFP1PRNPKDM4ENPSR1MAPK10 | |
| SCHEMBL12795599 | 0.73 | PRNP (0.61) | RXFP1PRNPKDM4ENPSR1MAPK10 | |
| SCHEMBL29177611 | 0.73 | RXFP1 (0.60) | RXFP1PRNPKDM4ENPSR1MAPK10 | |
| SCHEMBL10424110 | 0.73 | PRNP (0.61) | RXFP1PRNPKDM4ENPSR1MAPK10 | |
| SCHEMBL2817162 | 0.72 | CYP1A2 (0.58) | RXFP1PRNPKDM4ENPSR1MAPK10 | |
| SCHEMBL29979791 | 0.72 | CYP1A2 (0.58) | RXFP1PRNPKDM4ENPSR1MAPK10 | |
| SCHEMBL11326601 | 0.72 | RXFP1 (0.50) | RXFP1PRNPKDM4ENPSR1MAPK10 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-1062772-A | The method of making the sieve material of low internal stress reaches the sieve material that makes thus | STORK SCREENS BV (NL) | 1992-07-15 | — | — | CN | claimed |
| CN-107438598-A | QUINAZOLINE AND QUINOLINE COMPOUNDS AND USES THEREOF | 米伦纽姆医药公司 | 2017-12-05 | — | — | CN | disclosed |
| US-20160060249-A1 | QUINOLYL AMINES AS KINASE INHIBITORS | GLAXOSMITHKLINE INTELLECTUAL PROPERTY DEVELOPMENT LIMITED (GB) | 2016-03-03 | — | — | US | disclosed |
| EP-2603218-B1 | QUINOLYL AMINES AS KINASE INHIBITORS | GLAXOSMITHKLINE IP DEV LTD (GB) | 2016-03-02 | — | — | EP | disclosed |
| US-20140256949-A1 | QUINOLYL AMINES AS KINASE INHIBITORS | GLAXOSMITHKLINE INTELLECTUAL PROPERTY DEVELOPMENT LIMITED (GB) | 2014-09-11 | — | — | US | disclosed |
| CN-103601677-A | Preparation method of 2-alkylsulfenylquinoline derivative | UNIV TSINGHUA | 2014-02-26 | — | — | CN | disclosed |
| EP-2603218-A1 | QUINOLYL AMINES AS KINASE INHIBITORS | GlaxoSmithKline Intellectual Property Development Limited (GB) | 2013-06-19 | — | — | EP | disclosed |
| WO-2012021580-A1 | QUINOLYL AMINES AS KINASE INHIBITORS | GLAXO GROUP LIMITED (GB) | 2012-02-16 | — | — | WO | disclosed |
| US-20120041024-A1 | QUINOLYL AMINES AS KINASE INHIBITORS | GLAXOSMITHKLINE INTELLECTUAL PROPERTY DEVELOPMENT LIMITED (GB) | 2012-02-16 | — | — | US | disclosed |
| CN-1038605-C | Method for forming sieve material having low internal stress and sieve material so obtained | STORK SCREENS BV (NL) | 1998-06-03 | — | — | CN | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120041024-A1 | QUINOLYL AMINES AS KINASE INHIBITORS | ABL1, MAP3K20, MAP3K19 | RXFP1 1509/4885PRNP 3356/4885KDM4E 542/4885 |
| US-20160060249-A1 | QUINOLYL AMINES AS KINASE INHIBITORS | ABL1, MAP3K20, MAP3K19 | RXFP1 1509/4885PRNP 3356/4885KDM4E 542/4885 |
| US-20140256949-A1 | QUINOLYL AMINES AS KINASE INHIBITORS | ABL1, MAP3K20, MAP3K19 | RXFP1 1509/4885PRNP 3356/4885KDM4E 542/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.